Therapeutics News and Research

RSS

Osiris Therapeutics net income increases to $4.0 million for first quarter 2011

Osiris Therapeutics, Inc., the leading stem cell company focused on developing and marketing products to treat medical conditions in the inflammatory, autoimmune, cardiovascular, wound care and orthopedic areas, announced today its results for the first quarter ended March 31, 2011.

10 May 2011

Acceleron presents RAP-661 preclinical data in osteopenic mice at international meeting

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, presented preclinical data highlighting the significant anabolic bone effects in normal and osteopenic mice of RAP-661.

10 May 2011

Three Ontario projects set to further knowledge and discovery in biomonitoring, drug development

As part of the Genome Canada Large-Scale Applied Research Project Competition, which as a whole awarded over $58 million to 16 projects across the country, the researchers in Ontario will be focusing on biomonitoring, understanding gene function with the aim of identifying genes or proteins for drug targets, and the creation of synthetic antibodies to target cancers and other diseases.

9 May 2011

Unigene first quarter net loss decreases 58% to $6.6 million

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced first quarter financial results for the period ended March 31, 2011. The Company highlighted significant progress achieved in the first quarter with the execution of its turnaround strategy.

9 May 2011

Heptares, Shire sign deal to develop novel A2A antagonist for CNS disease treatment

Heptares Therapeutics today announced it has signed an exclusive option agreement with Shire Pharmaceuticals for a novel adenosine A2A antagonist discovered by Heptares and currently in preclinical development.

9 May 2011

New international project to create more mutant genes, address shortage of Cre resources

Local scientists are now part of an International team compiling an enormous bank of resources for research into the functions of all known genes. The development of these biological resources will eventually allow scientists to know how the human genome behaves in health and disease.

9 May 2011

Halozyme Therapeutics reports net loss of $9.6 million for first quarter 2011

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today reported financial results for the first quarter 2011.

7 May 2011

ImmunoCellular reports updated ICT-107 Phase I trial data in glioblastoma multiforme

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced updated long-term data from a Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme, the most common and aggressive form of brain cancer.

6 May 2011

CDRD reaches agreement with University of Calgary, UTI to develop promising drug candidates

The Centre for Drug Research and Development announced today the signing of affiliation agreements with both the University of Calgary and University Technologies International.

6 May 2011

Cell Therapeutics Board approves reverse stock split

Cell Therapeutics, Inc. today announced that the Company's Board of Directors approved a reverse stock split following the Company's receipt on May 3, 2011 of a notification of non-compliance from the staff of The NASDAQ Stock Market LLC.

6 May 2011

Omeros' PDE7 program expands addiction franchise

Omeros Corporation today announced that its phosphodiesterase 7 inhibitors demonstrated robust efficacy in animal models of nicotine addiction.

6 May 2011

COIN hosts nanobiotechnology event on nanomedicines and the regulatory path

The Center of Innovation for Nanobiotechnology (COIN) today announced the upcoming NanoBio Executive Roundtable event to be hosted at RTP Foundation in Durham, NC on May 17, 2011. This Roundtable will tackle regulatory issues surrounding nanomedicine commercialization. The “Nanomedicines and the Regulatory Path” Roundtable will kick off with a presentation from Katherine Tyner, Ph.D., a Chemist in the Center for Drug Evaluation and Research at the Food and Drug Administration (FDA).

5 May 2011

Acorda reports $0.7 million GAAP net loss for first quarter 2011

Acorda Therapeutics, Inc. today announced its financial results for the first quarter ended March 31, 2011.

5 May 2011

Promedior's PRM-151 clinical data in idiopathic pulmonary fibrosis to be presented at ATS 2011

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, today announced that data from a clinical study of PRM-151 will be presented at the 2011 American Thoracic Society International Conference, being held May 13-18, 2011 in Denver, CO.

5 May 2011

The Miami Project, InVivo Therapeutics collaborate to develop novel spinal cord injury treatments

InVivo Therapeutics, a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries, and The University of Miami Miller School of Medicine's Miami Project to Cure Paralysis, the world's most comprehensive spinal cord injury research center, today announced a strategic research collaboration for the development of novel SCI treatments.

5 May 2011

ZIOPHARM reports net loss of $39.0 million for first quarter 2011

ZIOPHARM Oncology, Inc, an oncology small molecule and synthetic biology drug development company, today reported its financial results for the three months ended March 31, 2011, and provided an update on the Company's activities in the first quarter.

5 May 2011

Research experts to speak at brain tumor educational conference

Patients, families and caregivers are invited to attend an educational conference covering many aspects of brain tumors May 14 at Cedars-Sinai Medical Center.

5 May 2011

TGen licenses ONCO-101 cancer drug to Syracuse

The Translational Genomics Research Institute has licensed its first drug, a unique compound that targets cancer tumors by modifying the actions of proteins.

5 May 2011

Selexys begins patient enrollment in SelG1 Phase I study for sickle cell disease

Selexys Pharmaceuticals announced today that it has initiated enrollment in a Phase I clinical study of its lead compound, SelG1, a humanized anti-P-selectin antibody.

5 May 2011

Durata receives positive EMA Scientific Advice on dalbavancin clinical development plan

Durata Therapeutics today announced the Company has received positive Scientific Advice from the European Medicines Agency on the pivotal clinical development plan for dalbavancin, Durata's long-acting, intravenous lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections.

4 May 2011

Therapeutics News and Research

Osiris Therapeutics net income increases to $4.0 million for first quarter 2011

Acceleron presents RAP-661 preclinical data in osteopenic mice at international meeting

Three Ontario projects set to further knowledge and discovery in biomonitoring, drug development

Unigene first quarter net loss decreases 58% to $6.6 million

Heptares, Shire sign deal to develop novel A2A antagonist for CNS disease treatment

New international project to create more mutant genes, address shortage of Cre resources

Halozyme Therapeutics reports net loss of $9.6 million for first quarter 2011

ImmunoCellular reports updated ICT-107 Phase I trial data in glioblastoma multiforme

CDRD reaches agreement with University of Calgary, UTI to develop promising drug candidates

Cell Therapeutics Board approves reverse stock split

Omeros' PDE7 program expands addiction franchise

COIN hosts nanobiotechnology event on nanomedicines and the regulatory path

Acorda reports $0.7 million GAAP net loss for first quarter 2011

Promedior's PRM-151 clinical data in idiopathic pulmonary fibrosis to be presented at ATS 2011

The Miami Project, InVivo Therapeutics collaborate to develop novel spinal cord injury treatments

ZIOPHARM reports net loss of $39.0 million for first quarter 2011

Research experts to speak at brain tumor educational conference

TGen licenses ONCO-101 cancer drug to Syracuse

Selexys begins patient enrollment in SelG1 Phase I study for sickle cell disease

Durata receives positive EMA Scientific Advice on dalbavancin clinical development plan

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News